Olema Pharmaceuticals (OLMA) Competitors $6.10 +0.31 (+5.35%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OLMA vs. KNSA, OCUL, MRVI, TVTX, AUPH, PRAX, ARVN, HROW, DAWN, and ARDXShould you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Ocular Therapeutix (OCUL), Maravai LifeSciences (MRVI), Travere Therapeutics (TVTX), Aurinia Pharmaceuticals (AUPH), Praxis Precision Medicines (PRAX), Arvinas (ARVN), Harrow (HROW), Day One Biopharmaceuticals (DAWN), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical preparations" industry. Olema Pharmaceuticals vs. Kiniksa Pharmaceuticals Ocular Therapeutix Maravai LifeSciences Travere Therapeutics Aurinia Pharmaceuticals Praxis Precision Medicines Arvinas Harrow Day One Biopharmaceuticals Ardelyx Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Does the media refer more to KNSA or OLMA? In the previous week, Olema Pharmaceuticals had 5 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 7 mentions for Olema Pharmaceuticals and 2 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 1.46 beat Olema Pharmaceuticals' score of 0.86 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, KNSA or OLMA? Kiniksa Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Does the MarketBeat Community favor KNSA or OLMA? Kiniksa Pharmaceuticals received 139 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. However, 67.39% of users gave Olema Pharmaceuticals an outperform vote while only 64.89% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKiniksa PharmaceuticalsOutperform Votes17064.89% Underperform Votes9235.11% Olema PharmaceuticalsOutperform Votes3167.39% Underperform Votes1532.61% Do institutionals & insiders believe in KNSA or OLMA? 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are held by insiders. Comparatively, 19.4% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings and valuation, KNSA or OLMA? Kiniksa Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals$384.10M3.87$14.08M-$0.14-147.07Olema PharmaceuticalsN/AN/A-$96.65M-$2.19-2.79 Is KNSA or OLMA more profitable? Olema Pharmaceuticals has a net margin of 0.00% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals-2.36% -7.31% -5.95% Olema Pharmaceuticals N/A -53.56%-47.86% Do analysts recommend KNSA or OLMA? Kiniksa Pharmaceuticals presently has a consensus price target of $36.60, indicating a potential upside of 77.76%. Olema Pharmaceuticals has a consensus price target of $27.00, indicating a potential upside of 342.62%. Given Olema Pharmaceuticals' higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Olema Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryKiniksa Pharmaceuticals and Olema Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OLMA vs. The Competition Export to ExcelMetricOlema PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$349.52M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-2.7910.5990.0517.18Price / SalesN/A195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book1.325.094.784.78Net Income-$96.65M$151.83M$120.31M$225.60M7 Day Performance-9.63%-2.13%-1.92%-1.23%1 Month Performance-22.49%-3.10%11.51%3.36%1 Year Performance-54.51%11.54%30.61%16.60% Olema Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OLMAOlema Pharmaceuticals2.0799 of 5 stars$6.10+5.4%$27.00+342.6%-54.1%$349.52MN/A-2.7980Insider TradeKNSAKiniksa Pharmaceuticals2.5299 of 5 stars$20.36+0.8%$36.60+79.8%+15.4%$1.47B$384.10M-147.36220Positive NewsOCULOcular Therapeutix3.6452 of 5 stars$9.03+3.9%$16.71+85.1%+116.8%$1.42B$58.44M0.00267Positive NewsMRVIMaravai LifeSciences4.4186 of 5 stars$5.54-2.3%$10.28+85.6%-15.7%$1.40B$276.92M-3.46580Analyst ForecastNews CoveragePositive NewsTVTXTravere Therapeutics2.7656 of 5 stars$17.65+1.9%$22.62+28.1%+106.0%$1.38B$145.24M-3.81460Positive NewsAUPHAurinia Pharmaceuticals2.3312 of 5 stars$9.55+1.9%$10.00+4.7%+1.3%$1.37B$220.36M-63.33300PRAXPraxis Precision Medicines2.4017 of 5 stars$71.98+2.6%$146.33+103.3%+323.0%$1.34B$2.45M-7.06110High Trading VolumeARVNArvinas2.0251 of 5 stars$19.35-0.8%$63.50+228.2%-49.3%$1.33B$78.50M-4.18445HROWHarrow2.3891 of 5 stars$36.88+3.9%$63.00+70.8%+241.9%$1.31B$130.19M-37.77182Positive NewsDAWNDay One Biopharmaceuticals1.6211 of 5 stars$12.74-0.1%$35.71+180.3%-7.7%$1.28B$101.95M-12.3860ARDXArdelyx3.6907 of 5 stars$5.39+3.3%$10.42+93.3%-18.9%$1.28B$251.85M-17.80267 Related Companies and Tools Related Companies KNSA Alternatives OCUL Alternatives MRVI Alternatives TVTX Alternatives AUPH Alternatives PRAX Alternatives ARVN Alternatives HROW Alternatives DAWN Alternatives ARDX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OLMA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OLMA Stock Alerts